Simvastatin add-on Treatment to Standard Antidepressant Therapy in Patients With Comorbid Obesity and Major Depression (SIMCODE)

STATUS

Recruiting
End date

Jun 26, 2023
participants needed

160
sponsor

Charite University, Berlin, Germany

Send

Updated on 1 March 2022

See if I qualify

diabetes

cardiovascular disease

insulin

ketamine

body mass index

depression

bipolar disorder

psychiatric disorder

antidepressants

psychotropic drugs

suicide

depressive episode

schizophrenia

major depressive disorder

citalopram

bariatric surgery

electroconvulsive therapy

antidepressant therapy

Summary

Major depressive disorder (MDD) and obesity are major contributors to impaired health worldwide. Statins are among the most prescribed medications with well-established safety and efficacy. Statins are recommended in primary prevention of cardiovascular disease, which has been linked to both MDD and obesity. Moreover, statins are promising candidates to treat MDD because a meta-analysis of pilot randomized controlled trials has found antidepressive effects of statins as adjunct therapy to antidepressants. However, no study so far has tested the antidepressive potential of statins in patients with MDD and comorbid obesity. Therefore, we hypothesize that Simvastatin add-on to standard antidepressant Escitalopram will improve depression to a greater extent than add-on placebo in patients with comorbid obesity and major depression. We will randomize 160 obese MDD patients at 8 recruiting centers to either Simvastatin or placebo as add-on to Escitalopram for 12 weeks. If successful, our trial would have immediate impact on clinical practice given the fact that Simvastatin and Escitalopram are available as inexpensive generic drugs with established safety.

Details

Condition	Depressive Disorder, Major, Obesity
Treatment	simvastatin 40mg, Placebo Oral Tablet
Clinical Study Identifier	NCT04301271
Sponsor	Charite University, Berlin, Germany
Last Modified on	1 March 2022

How understandable was the trial content above?

Hard to understand

Easy to understand

Eligibility		Yes	No	Not Sure
Inclusion Criteria
	Written informed consent is present
	The patient has the capacity to give consent (He/she is able to understand the nature and anticipated effects/side effects of the proposed medical intervention)
	The patient has a major depressive episode according to DSM 5 (Diagnostic and Statistical Manual of Mental Disorders 5th Edition)
	The patient has a score of 18 in the Montgomery-Asberg Depression Rating Scale (MADRS)
	The patient has a body mass index 30
	The patient's age is between 18 and 65 years ( 18 und 65)
	The patient has not given childbirth within the 6 months prior to study entry and is not breastfeeding
	In case of non-psychotropic medication: The patient received stable pharmacological medication for at least 14 days prior to study entry (any changes in medication dose or frequency of therapy must be answered with no)
	The patient did not take antidepressants during the last 7 days prior to study entry (discontinuation of effective medication to enable study participation is prohibited)
	The patient did not receive prior treatment with Escitalopram in index episode
	The patient had less than three (<3) trials with antidepressants in index episode
	The patient does not have a history of non-response to Escitalopram
	The patient did not receive treatment with ketamine, irreversible MAO inhibitor (e.g. tranylcypromine), electroconvulsive therapy (ECT) or other stimulatory treatments in index episode
	The patient does not meet any of the following criteria: schizophrenia, schizoaffective disorder, bipolar disorder
	The patient is not diagnosed with dementia and does not have moderate or severe impairment of general cognitive function according to clinical impression
	The patient does not have clinically relevant elevated liver enzymes [GOT or GPT > 3 x upper limit normal (ULN)] and does not have elevated Carbohydrate Deficient Transferrin (CDT) 2.4 %
	The patient does not meet the criteria for alcohol use disorder (DSM-5: 303.90; ICD-10: F10.20) or substance use disorder (DSM-5: 304; ICD-10: F11.20 - F19.20) in M.I.N.I. for DSM-5 and a urine/serum drug screening is negative (except for benzodiazepines and opiates)
	The patient does not have a history of suicide attempt
	The patient does not have diagnosed epilepsy or increased bleeding diathesis or a history of angle closure glaucoma or other glaucomas
	The patient did not have bariatric surgery prior to study entry
	The patient does not have a known allergy or contraindication against Escitalopram or Simvastatin
	The patient does not meet any of the following criteria: hereditary muscle disease, known history of rhabdomyolysis, elevated creatine kinase (CK) outside of the sex-specific reference intervals, history of muscular symptoms under treatment with statins or fibrates
	The patient does not have elevated TSH level outside of the age- and sex-specific refer-ence intervals
	The patient does not have insulin-dependent diabetes mellitus
	The patient does not have uncontrolled hepatic disorder, renal or cardiovascular disease
	The patient does not have untreated hypothyroidism
	The patient does not have a history of myocardial infarction or stroke
	The patient does not have symptomatic peripheral arterial disease
	The patient does not have monogenic familial hypercholesterolemia
	The patient does not have clinically significant laboratory abnormalities
	The patient did not participate in other interventional trials during the 6 months before and at the time of this trial
	The patient is not an employee of the investigator study site, or a family member of the employees or the investigator, or otherwise dependent on the sponsor, the investigator or the investigator study site
Exclusion Criteria
	The patient has current use of statins (for visits 2-6 applies: except for IMP Simvastatin)
	The patient has current use of antidepressants (for visits 2-6 applies: except for standard medication Escitalopram)
	The patient has acute suicidal tendencies (MADRS Item 10 > 4)
	The patient uses potent CYP3A4-inhibitors (e.g. clarithromycin, erythromycin, HIV protease inhibitors - see "Risks, adverse drug reactions, drug interactions, restrictions, contraindications, procedures in case of emergency")
	The patient uses potent CYP3A4 inductors (Carbamazepine, Efavirenz, Nevirapine, Etravirine)
	The patient uses Fibrates, Amiodarone, Amlodipine, Verapamil, Fluconazol, Diltiazem, Fusidic acid, Niacin or Lomitapide or BCRP-Inhibitors (e.g. Elbasvir or Grazoprevir)
	The patient uses Gemfibrozil, Ciclosporin or Danazol
	The patient has known hypersensitivity to other ingredients of Simvastatin and Escitalopram [butylated hydroxyanisole, microcrystalline celluose, citric acid, starch, lactose, magnesium stearate, hypromellose, talc, titanium dioxide, iron oxides, colloidal silicon dioxide, croscarmellose sodium, polyethylene glycol]
	The patient uses medication that is associated with QTc-prolongation [antiarrhythmics class IA and III, antipsychotics (e.g. Haloperidol), phenothiazines, tricyclic antidepressants, antibiotics (e.g. Moxifloxacin), and certain antihistaminergic drugs (e.g. Astemizol, Mizolastine)]
	The patient has clinically significant abnormalities in 12-lead ECG (e.g. QTc-prolongation 500 ms or increase 60 ms from baseline visit)
	The patient is pregnant
	The patient with childbearing potential is not willing to use an acceptable form of contraception (defined as Pearl index < 1)
	The patient has current use of psychotropic medication (e.g. antipsychotics, anticonvulsants, lithium or St. John's Wort) except for benzodiazepines, non-benzodiazepines and opiates
	The patient uses nonselective, irreversible monoamine oxidase (MAO) inhibitor (e.g. Tranylcypromine) or selective, reversible inhibitor of monoamine oxidase A (e.g. Moclobemide) or the nonselective, reversible monoamine oxidase inhibitor Linezolid
	The patient is unwilling to consent to saving, processing and propagation of pseudonymized medical data for study reasons
	The patient is legally detained in an official institution

How to participate?

Step 1 Connect with a study center

Select a site
Send a message

You have contacted , on

Your message has been sent to the study team at ,

A copy of the message has been sent to your email

What happens next?

You can expect the study team to contact you via email or phone in the next few days.
Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Primary Contact

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).

Step 2 Get screened

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

Step 3 Enroll in the clinical study

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Step 4 Get your study results

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Browse trials for

diabetes

cardiovascular disease

major depressive disorder

citalopram

bariatric surgery

electroconvulsive therapy

antidepressant therapy

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Study Definition

Wikipedia

Simvastatin add-on Treatment to Standard Antidepressant Therapy in Patients With Comorbid Obesity and Major Depression (SIMCODE)